Replies to post #328556 on Amarin Corp Plc (AMRN)

[rafunrafun]

To cancel the VHTG indication from the label is futile, the indication will exist independently from Vascepa ('s label) ... however modify the coverage agreements - terminate the VHTG part - is a brilliant step. Let's hope all HCP will do the same. (Assumping it is Amarin's action, plan going forward ... let the 10% of the market for the gV WITHOUT coverage.)

How does this help Amarin?

Yes, this insurance won't cover VHTG but why does it mean that substitutions (for TG 150-500) from V to gV will not occur at pharmacy?

Could insurance say that we don't accept gV? That would be the ultimate goal for Amarin.